What one share of Hepion Pharmaceuticals holds
Pharmaceuticals, Inc. (we, our, or us) is a medical diagnostic company headquartered in Morristown, New Jersey, that was previously focused on the development of drug therapy for treatment of chronic liver diseases. Our cyclophilin inhibitor, rencofilstat (formerly CRV431), was being developed to offer benefits to address multiple complex pathologies related to the progression of liver disease.
Hepion Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.25 |
|---|---|
| Cash and investments | $0.06 |
| Debt | $0.00 |
| Book value | $0.04 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | $0.00 | −$465.52 | $1.86 | −$446.07 | — | $1,220 |
| 2022 | $0.00 | −$594.75 | $0.21 | −$458.85 | — | $654.02 |
| 2023 | $0.00 | −$616.07 | $0.18 | −$515.05 | — | $75.55 |
| 2024 | — | −$107.35 | — | — | — | −$13.39 |
| 2025 | — | −$0.88 | — | — | — | $0.23 |
Common questions about Hepion Pharmaceuticals
How much does one share of Hepion Pharmaceuticals earn?
Over the last 12 months, Hepion Pharmaceuticals lost $0.25 for each share.
Does Hepion Pharmaceuticals pay a dividend?
Hepion Pharmaceuticals didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Hepion Pharmaceuticals’s book value per share?
Hepion Pharmaceuticals’s book value is $0.04 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Hepion Pharmaceuticals have?
Each share of Hepion Pharmaceuticals has $0.06 of cash and investments and $0.00 of debt, as of June 30, 2026.
Has Hepion Pharmaceuticals bought back shares?
Hepion Pharmaceuticals’s share count rose about 13286% from 2021 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.